Clinical features and outcome of the patients with sinonasal tract diffuse large B-cell lymphoma in the pre-rituximab and rituximab eras

Show full item record



Permalink

http://hdl.handle.net/10138/312895

Citation

Vähämurto , P , Mannisto , S , Pollari , M , Karjalainen-Lindsberg , M-L , Mäkitie , A A & Leppä , S 2019 , ' Clinical features and outcome of the patients with sinonasal tract diffuse large B-cell lymphoma in the pre-rituximab and rituximab eras ' , European Journal of Haematology , vol. 102 , no. 6 , pp. 457-464 . https://doi.org/10.1111/ejh.13225

Title: Clinical features and outcome of the patients with sinonasal tract diffuse large B-cell lymphoma in the pre-rituximab and rituximab eras
Author: Vähämurto, Pauli; Mannisto, Susanna; Pollari, Marjukka; Karjalainen-Lindsberg, Marja-Liisa; Mäkitie, Antti A.; Leppä, Sirpa
Contributor organization: HUS Head and Neck Center
Department of Oncology
HUS Comprehensive Cancer Center
ATG - Applied Tumor Genomics
Research Program in Systems Oncology
Research Programs Unit
Korva-, nenä- ja kurkkutautien klinikka
Genome-Scale Biology (GSB) Research Program
Department of Pathology
Helsinki University Hospital Area
Department of Ophthalmology and Otorhinolaryngology
Date: 2019-06
Language: eng
Number of pages: 8
Belongs to series: European Journal of Haematology
ISSN: 0902-4441
DOI: https://doi.org/10.1111/ejh.13225
URI: http://hdl.handle.net/10138/312895
Abstract: Purpose Sinonasal tract diffuse large B-cell lymphoma (SNT-DLBCL), a rare extranodal lymphoma, is not well characterized. We performed a population-based study to determine cell-of-origin, clinical presentation and impact of rituximab (R) and central nervous system (CNS) directed chemotherapy on survival. Patients and methods Patients with SNT-DLBCL were identified from pathology databases. Clinical information was collected and outcomes between different treatment modalities evaluated. Results Thirty-two percent of the patients had germinal centre B-cell phenotype. Forty-six patients were treated with curative intent using CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or CHOP-like chemotherapy, 21 (46%) before and 25 (54%) in the R-era. Additionally, 24 (52%) received CNS-directed chemotherapy. Addition of R to chemotherapy reduced the risk of progression (RR = 0.368, 95% CI 0.138-0.976, P = 0.045) and death (RR = 0.245, 95% CI 0.068-0.883, P = 0.032), and translated into better survival (5-year PFS, 67% vs 38%, P = 0.037; 5-year OS, 81% vs 48%, P = 0.020). CNS-directed chemotherapy reduced the risk of progression (RR = 0.404, 95% CI 0.159-1.029, P = 0.057) and death (RR = 0.298, 95% CI 0.093-0.950, P = 0.041), and translated into favorable survival (5-year PFS, 67% vs 32%, P = 0.050; 5-year OS 82% vs 43%, P = 0.030). Conclusion Patients with SNT-DLBCL benefit from rituximab and CNS-directed chemotherapy.
Subject: clinical presentation
diffuse large B-cell lymphoma
sinonasal tract
survival
DETUDES DES LYMPHOMES
NON-HODGKINS-LYMPHOMA
ELDERLY-PATIENTS
BIOLOGICAL CHARACTERIZATION
PLUS CYCLOPHOSPHAMIDE
CHOP CHEMOTHERAPY
YOUNG-PATIENTS
TRIAL
SURVIVAL
VINCRISTINE
3122 Cancers
Peer reviewed: Yes
Usage restriction: openAccess
Self-archived version: acceptedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
V_h_murto_et_al ... Journal_of_Haematology.pdf 855.2Kb PDF View/Open
V_h_murto_et_al ... Journal_of_Haematology.pdf 713.7Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record